1 Professor and Head, Dept. of Pediatrics, Government Medical College & Hospital, Nagpur.
2 Senior Resident, Dept. of Pediatrics, Government Medical College & Hospital, Nagpur.
3 Former Scientist G & Director In-Charge, National Institute of Immunohaematology, Mumbai.
4 Consultant, Fetal Medicine and Fetal Therapy, Ruby Hall Clinic &Director, Kangaroo Cradle; The Fetal Care Clinic, Pune.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Sickle cell disease (SCD) is the
most common inherited hemoglobinopathy and is associated with increased risk of
complications and early mortality. Nowadays, with improved health care
facilities, antibiotic prophylaxis, vaccination, and availability of drugs like
hydroxyurea, the life expectancy of SCD patients has improved. More women are
reaching reproductive age group and are expressing their desire to reproduce.
Though SCD adversely affects pregnancy, leading to increased incidence of
maternal and perinatal complications like pre-eclampsia, preterm labor, IUGR,
abortions etc., adequate care throughout pregnancy ensures a better outcome.
Also, recent advancements in the fields of prenatal diagnosis and
pre-implantation genetic diagnosis, help couples suffering from SCD to have a
healthy baby. This paper focuses on the effects of SCD on pregnancy outcomes
and effective management of complications during pregnancy, also comparing
maternal and perinatal outcomes in studies conducted in different countries.
The second part of the paper summarizes pregnancy management in SCD for better
maternal and fetal outcomes.
Material and Methods
|Table 1. Maternal outcomes in SCD.|
|Table 2. Perinatal outcomes in SCD.|
Management of Adverse Events in Pregnancy with SCD
Pregnancy Management in SCD
Hydroxyurea and Pregnancy